THE first-ever adaptive clinical trial for Australians living with multiple sclerosis (MS) will seek to reverse neurological damage caused by the progressive condition.
With an initial $4m in funding, the trial, commencing in Jan 2024, will enable researchers to investigate the potential benefits of several pharmacy medications simultaneously, giving hope to those with one of the most debilitating forms of MS who currently have extremely limited treatment options.
Working with a national and international group of clinicians and researchers, the trial will test two repurposed drugs alongside each other, providing more timely results about whether the treatments are working.
President of MS Australia A/Prof Des Graham said, "with a $3m grant from MSWA and a $1m grant from MS Australia, this revolutionary adaptive trial provides tremendous promise for those living with progressive MS in Australia".
The PLATYPUS trial will be rolled out across Australia through a collaboration of 20 academic and healthcare institutions and aims to recruit more than 250 participants from around the country.
The above article was sent to subscribers in Pharmacy Daily's issue from 29 Nov 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 29 Nov 23
